{"id":"W2947257322","doi":"10.1200/jco.2019.37.15_suppl.tps5598","title":"DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bevacizumab; Olaparib; Oncology; Internal medicine; BRCA mutation; Ovarian cancer; Cancer; PARP inhibitor; Chemotherapy; Maintenance therapy; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001478356,0.001811175,0.001823373,0.0003676595,0.0003845068,0.001161545,0.001139231,0.001667435,0.006993632],"category_scores_gemma":[0.001522708,0.0007585103,0.001489578,0.0003208264,0.0009789043,0.001044368,0.0005400747,0.003321095,0.001016493],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001010443,"about_ca_system_score_gemma":0.001422736,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001299406,"about_ca_topic_score_gemma":0.003924954,"domain_scores_codex":[0.9995893,0.0002115291,0.00001846206,0.00007168869,0.000029836,0.0000792614],"domain_scores_gemma":[0.9992642,0.0001450796,0.0001542124,0.0000471399,0.00003790985,0.0003514076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9532173,0.01964615,0.0009702978,0.0007367627,0.0006833806,0.00005083,0.00008256065,0.0004359348,0.003562288,0.0002157565,0.002370057,0.01802867],"study_design_scores_gemma":[0.9315699,0.06551884,0.0008875335,0.00002676572,0.0002281934,0.00005198305,0.00002905298,0.000336753,0.0003000832,0.0001486691,0.0008912146,0.00001098316],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.982347,0.003843501,0.0005786598,0.001229443,0.0007378166,0.005927214,0.001891636,0.0001739141,0.003270841],"genre_scores_gemma":[0.973659,0.003322479,0.002175354,0.002363706,0.0004094525,0.00872873,0.00276821,0.00004293754,0.006530002],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006993632,"threshold_uncertainty_score":0.02339602,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0223891265192967,"score_gpt":0.3849379027665236,"score_spread":0.3625487762472269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}